InsiderTrades

Form 4 for CLDX Celldex Therapeutics, Inc.

Accepted 2022-08-17 00:00:00 ET · period of report 2022-08-15 · accession 0001415889-22-008769 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-08-17 2022-08-15 CLDX Marucci Anthony S Pres, CEO, Dir S - Sale+OE $37.66 -120.0K 27.7K -81% -$4.52M
DM 2022-08-17 2022-08-15 CLDX Marucci Anthony S Pres, CEO, Dir M - OptEx $5.12 +120.0K 147.7K +433% +$614.4K
DM 2022-08-17 2022-08-15 CLDX Marucci Anthony S Pres, CEO, Dir M - OptEx $0.00 -120.0K 25.0K -83% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-08-15 S D 120,000 $37.66 27,692 D — — (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.39 to $37.95 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
2 Common Common Stock 2022-08-15 M A 75,000 $2.78 102,692 D — — (F1) Includes 461 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
3 Common Common Stock 2022-08-15 M A 45,000 $9.02 147,692 D — — (F2) This option was previously reported as covering 1,075,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the reverse stock split that occurred on February 8, 2019.
4 Derivative Incentive Stock Option 2022-08-15 M D 45,000 $0.00 26,665 D $9.02 · — to 2028-06-13 45,000 Common Stock (F2) This option was previously reported as covering 1,075,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the reverse stock split that occurred on February 8, 2019. (F5) As of June 13, 2022, the option is fully vested.
5 Derivative Incentive Stock Option 2022-08-15 M D 75,000 $0.00 25,000 D $2.78 · — to 2029-06-19 75,000 Common Stock (F4) 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.